|
gptkbp:instance_of
|
gptkb:monoclonal_antibody
|
|
gptkbp:bfsLayer
|
3
|
|
gptkbp:bfsParent
|
gptkb:Genentech
|
|
gptkbp:activities
|
HE R2 receptor blockade
|
|
gptkbp:appointed_by
|
intravenous infusion
|
|
gptkbp:approves
|
gptkb:1998
gptkb:FDA
|
|
gptkbp:can_be_used_with
|
gptkb:docetaxel
gptkb:pertuzumab
gptkb:carboplatin
chemotherapy
|
|
gptkbp:clinical_trial
|
gptkb:trastuzumab-dkst
gptkb:trastuzumab-pkrb
gptkb:trastuzumab-qyzy
Phase III
|
|
gptkbp:contraindication
|
pregnancy
lactation
hypersensitivity to trastuzumab
|
|
gptkbp:developed_by
|
gptkb:Genentech
|
|
gptkbp:discontinued
|
in patients with severe heart failure
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Herceptin
|
|
gptkbp:indication
|
HE R2-positive gastric cancer
HE R2-positive breast cancer
|
|
gptkbp:ingredients
|
C6475 H10000 N1715 O2100 S44
|
|
gptkbp:invention
|
gptkb:2019
|
|
gptkbp:is_monitored_by
|
cardiac function
infusion reactions
|
|
gptkbp:is_used_for
|
treatment of breast cancer
treatment of gastric cancer
|
|
gptkbp:manager
|
intravenous
|
|
gptkbp:marketed_as
|
gptkb:Europe
gptkb:Australia
gptkb:United_States
gptkb:Native_American_tribe
gptkb:trastuzumab
|
|
gptkbp:population
|
gptkb:Person
adults
|
|
gptkbp:price
|
high
|
|
gptkbp:provides_information_on
|
ASCO guidelines
NCCN guidelines
|
|
gptkbp:requires
|
available online
|
|
gptkbp:research_areas
|
gptkb:Company
gptkb:vaccine
gptkb:drug
oncology
|
|
gptkbp:shelf_life
|
24 months
|
|
gptkbp:side_effect
|
headache
nausea
diarrhea
infusion reactions
cardiotoxicity
|
|
gptkbp:storage
|
2 to 8 ° C
|
|
gptkbp:targets
|
HE R2 protein
|
|
gptkbp:weight
|
148 k Da
|